Bismuth absorption from 205Bi-labelled pharmaceutical bismuth compounds used in the treatment of peptic ulcer disease.
The absorption of bismuth from five 205Bi-labelled pharmaceutically used bismuth compounds was studied in man. From single oral doses of all compounds under investigation only less than 0.1% bismuth was absorbed and excreted with the urine. A significantly higher absorption was observed from the colloidal bismuth subcitrate (0.042% of the dose) and the basic bismuth gallate (0.038%) than from the basic bismuth salicylate, nitrate, and aluminate (0.005-0.002%). No retention of bismuth in the whole body was found from the single dose experiment. The biologic fast-term half-lives of absorbed bismuth were calculated to be 0.12 and 1.5 days.
Dresow
B
B
Dept. of Medical Biochemistry, Eppendorf University Hospital, Hamburg, Germany.
Fischer
R
R
Gabbe
E E
EE
Wendel
J
J
Heinrich
H C
HC
D000328:Adult; D000535:Aluminum / Q000493:pharmacokinetics; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001682:Biological Availability; D001729:Bismuth / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005707:Gallic Acid / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D010437:Peptic Ulcer / Q000188:drug therapy*; D011868:Radioisotopes
D000897:Anti-Ulcer Agents; D009566:Nitrates; D009942:Organometallic Compounds; D011868:Radioisotopes; C065545:bismuth nitrate; D005707:Gallic Acid; D000535:Aluminum; C002791:bismuth tripotassium dicitrate; C065544:bismuth aluminate; D001729:Bismuth; C002170:bismuth subgallate